Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

December 12th 2023

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Financial Navigation Program May Alleviate Cost Burden Associated With Multiple Myeloma

December 12th 2023

Utilization of a financial navigation program is feasible for reducing cost burden and improving quality of life in patients with multiple myeloma who are more likely to experience financial toxicity and have difficulty accessing appropriate resources and support services.

Anito-Cel Elicits Responses With Manageable Safety in Relapsed/Refractory Multiple Myeloma

December 12th 2023

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

December 12th 2023

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed

December 12th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

December 11th 2023

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

December 10th 2023

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Ultrasensitive BCMA CARs Deliver Responses With Tolerable Safety in R/R Multiple Myeloma

December 10th 2023

The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy is safe and feasible in patients with relapsed/refractory multiple myeloma.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

December 9th 2023

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Dr Braunstein on the Evolution of ASCT in Multiple Myeloma

November 29th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Improves PFS in R/R Multiple Myeloma

November 27th 2023

Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.

Ongoing Research Aims to Better Define Role of ASCT in Myeloma

November 27th 2023

Marc J. Braunstein, MD, PhD, discusses the current role of autologous stem cell transplant for patients with multiple myeloma, highlighted the key factors used to determine patient eligibility, and detailed ongoing research centered around autologous stem cell transplant.

Dr Davies on Addressing Global Gaps in Multiple Myeloma Care

November 22nd 2023

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Dr Richter on the Current State of Bispecific Antibodies in Multiple Myeloma

November 21st 2023

Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.

Ongoing Research Aims to Bring Bispecific Antibodies to Earlier Settings and Novel Combinations in Myeloma

November 21st 2023

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.

FDA’s ODAC to Review Data for Ide-Cel in Triple-Class Exposed R/R Myeloma

November 20th 2023

The FDA’s Oncologic Drugs Advisory Committee will meet to review data from the supplemental biologics license application seeking the approval of idecabtagene vicleucel for use in earlier lines of treatment for patients with triple-class exposed relapsed/refractory multiple myeloma.

Dr Braunstein on Stem Cell Transplant Eligibility Criteria in Multiple Myeloma

November 9th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.

Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma

November 8th 2023

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

BCMA-Directed Therapies Broaden Myeloma Arsenal and Could Reshape Earlier Lines of Treatment

November 6th 2023

Jesus Berdeja, MD, discussed considerations when choosing between bispecific antibodies and CAR T-cell therapy for patients with multiple myeloma, clinical trials that may move CAR T-cell therapy into earlier lines, and research with agents directed at targets other than BCMA.

Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

November 1st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bcmm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.